What does Orforglipron do?

The supplied evidence describes orforglipron as an oral, once-daily GLP-1 receptor agonist being researched for weight management, type 2 diabetes, and convenience compared with injectable GLP-1 options. The regulatory-status statements conflict, so approval status needs review before publication.

How does Orforglipron work?

Orforglipron is reported to act at the GLP-1 receptor. The source links that receptor activity with lower appetite, slower gastric emptying, and insulin release when glucose is elevated. It is described as a non-peptide small molecule, which distinguishes it from peptide GLP-1 drugs such as semaglutide.

Is Orforglipron FDA approved?

The source is internally inconsistent. Some fields say FDA approved, including an April 2026 obesity/overweight indication and the brand name Foundayo, while other passages say it was not yet approved and was under regulatory review as of mid-2026. This draft preserves the conflict instead of treating either statement as settled.

What are the side effects of Orforglipron?

Reported events include diarrhea at 19-26%, nausea at 13-18%, vomiting, gastrointestinal events described as mild to moderate, and increased pulse. The source also includes an investigational/not-yet-approved caution, which conflicts with approval claims elsewhere in the same input.

What is the typical dose of Orforglipron?

The community field says limited community data are available and directs reviewers to research dosing. The research dosing row reports 12-45mg once daily as an oral tablet in Phase 3 clinical trial data. This is a source summary, not dosing guidance.

This entry is not a peptide · It is included because this compound is commonly discussed alongside peptide research.

Weight Loss FDA Approved - approved for specific uses

Orforglipron

Also known as: LY3502970, OWL833

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

Oral small-molecule GLP-1 receptor agonist researched for obesity and type 2 diabetes.

Status

FDA Approved

Evidence level: human clinical evidence

Typical dose

12–45mg

Oral tablet daily

Researched for

Oral weight-loss option, diabetes, convenience

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

FDA approved - FDA-approved for specific uses with established human evidence

Use the tools

In plain language

Oral, once-daily receptor described as a non- small molecule.
Researched for obesity, type 2 diabetes, and convenience as an oral option.
Source reports multiple Phase 3 programs, while approval-status fields conflict and require review.
Typical community dose information is limited; the research row lists 12-45mg once daily.
Reported adverse events are mainly gastrointestinal, with diarrhea, nausea, and vomiting listed.

How it's thought to work

Orforglipron is described as a small-molecule receptor . The supplied mechanism text connects GLP-1 receptor activation with appetite reduction, slower gastric emptying, and glucose-dependent insulin release. The same evidence emphasizes oral stability as the chemistry-based distinction from peptide GLP-1 agents, not a different receptor target.

What the research shows

Where the research stands

The source summarizes a late-stage clinical program. It reports ATTAIN-1 as a 72-week obesity trial in which three dose groups outperformed placebo for weight loss, with full results said to appear in the New England Journal of Medicine. ATTAIN-2 is described in adults with obesity and type 2 diabetes, with weight loss and changes in waist circumference, blood pressure, non-HDL cholesterol, and triglycerides. For diabetes, ACHIEVE-1 is characterized as a Phase 3 success for an oral small-molecule agent, and ACHIEVE-3 is reported as a head-to-head comparison where orforglipron exceeded oral semaglutide on A1C and weight. The same source frames the main advance as oral delivery rather than a new GLP-1 mechanism.

What it shows

✓ Human clinical evidence

FDA-approved for specific uses with established human evidence

△ Limitations

Use only according to approved labeling and qualified medical guidance.

Bottom line: FDA approved in 2026 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. FDA approved (2026)

Typical dosing

CommunityCommunity dataset

Limited community data available

See research protocols

Range: See research dosing

Community-reported row points to research protocols and research dosing; regulatory text in this row conflicts with other approval-status statements, and commerce details were omitted. · Oral tablet daily

Research dosing

Indication-specificApproved for specific uses - study doses are indication-specific

Doses observed in studies

12-45mg once daily

Clinical Trial Data - Phase 3 Clinical Trials

Use only according to approved labeling and qualified medical guidance.

Duration: Long-term use expected
Administration: Oral tablet daily

Timing & administration

Food recommendation

With or without food

Why this timing?

FDA labeling requires once-daily administration and permits use with or without food; it does not specify a preferred clock time.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Diarrhea
Nausea
Vomiting
Gastrointestinal events
Pulse increase
Investigational/not-yet-approved caution

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Orforglipron

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Orforglipron

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows